$30.53 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Vericel

Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.. Its autologous cell therapy products include Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Stock Analysis

last close $28.13
1-mo return 3.2%
3-mo return 2.8%
avg daily vol. 367.4T
52-week high 60.24
52-week low 22.42
market cap. $1.3B
forward pe 3516
annual div. -
roe -10.1%
ltg forecast -
dividend yield -
annual rev. $155M
inst own. -

Subscribe now for daily local and international financial news